Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Ovarian Neoplasms

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 20 articles:
HTML format
Text format



Single Articles


    July 2019
  1. TOMAO F, Panici PB, Tomao S
    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    J Natl Cancer Inst. 2019 Jul 9. pii: 5530203. doi: 10.1093.
    PubMed     Text format    


    June 2019
  2. VAN DIEST PJ, Zweemer RP, Piek JMJ
    Re: the Association between hysterectomy and ovarian cancer risk: A population-based record-linkage study.
    J Natl Cancer Inst. 2019 Jun 13. pii: 5514539. doi: 10.1093.
    PubMed     Text format    


    May 2019
  3. VOS JR, Fakkert IE, de Hullu JA, van Altena AM, et al
    Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    J Natl Cancer Inst. 2019 May 11. pii: 5488012. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  4. DIXON-SUEN SC, Webb PM, Wilson LF, Tuesley K, et al
    The Association between hysterectomy and ovarian cancer risk: A population-based record-linkage study.
    J Natl Cancer Inst. 2019 Feb 11. pii: 5308404. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018

  5. Corrigendum to "Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer".
    J Natl Cancer Inst. 2018 Jun 28. pii: 5046631. doi: 10.1093.
    PubMed     Text format    


    May 2018
  6. YEUNG TL, Sheng J, Leung CS, Li F, et al
    Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
    J Natl Cancer Inst. 2018 May 31. pii: 5026201. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. TRABERT B, Poole EM, White E, Visvanathan K, et al
    Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
    J Natl Cancer Inst. 2018 May 31. pii: 5026198. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. TRABERT B, Waterboer T, Idahl A, Brenner N, et al
    Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.
    J Natl Cancer Inst. 2018 May 21. pii: 5001107. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  9. CRAMER DW, Elias KM
    Perspectives on Ovarian Cancer From SEER: Today and Tomorrow.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990609. doi: 10.1093.
    PubMed     Text format    


  10. PERES LC, Cushing-Haugen KL, Kobel M, Harris HR, et al
    Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990606. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  11. HILLMAN RT, Chisholm GB, Lu KH, Futreal PA, et al
    Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  12. VISVANATHAN K, Wang TL, Shih IM
    Precancerous Lesions of Ovarian Cancer-A US Perspective.
    J Natl Cancer Inst. 2017 Dec 21. pii: 4769851. doi: 10.1093.
    PubMed     Text format    


    November 2017
  13. FERRARA N
    Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  14. BAIS C, Mueller B, Brady MF, Mannel RS, et al
    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  15. DOHERTY JA, Jensen A, Kelemen LE, Pearce CL, et al
    Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    August 2017
  16. SCHMIDT MK, van den Broek AJ, Tollenaar RA, Smit VT, et al
    Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    July 2017
  17. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  18. PREVIS RA, Armaiz-Pena GN, Ivan C, Dalton HJ, et al
    Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    March 2017
  19. BRASKY TM, Felix AS, Cohn DE, McMeekin DS, et al
    Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
    J Natl Cancer Inst. 2017;109:1-10.
    PubMed     Text format     Abstract available


    October 2016
  20. FILLON M
    New Guidelines for Treating Ovarian Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: